This concept is supported by an animal study by Veillard et al. [18] in which treatment of hypercholesterolemic mice with the CCR5 antagonist Met-RANTES reduced progression of atherosclerosis and CCL5/RANTES inhibition attenuated myocardial reperfusion injury in atherosclerotic mice [14]. This evidence concerns the gene CCL5 and atherosclerosis.